Novo Nordisk A/S
Wegovy helps reduce heart failure symptoms in obese people, study says
A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023. Jim Vondruska | Reuters Wegovy, the popular weight loss drug from Novo Nordisk, significantly reduced symptoms of a common type of heart failure in patients with obesity, according to a late-stage clinical […]
Read More
Weight loss drugs boost sales at retail pharmacies, but they may not help profits much
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters Drugmakers aren’t the only ones feeling the impact of the weight loss industry gold rush. Retailers with pharmacy businesses, such […]
Read More
Here are some of the companies saying weight loss drugs could impact their business
The impact of new weight loss treatments is being felt well beyond the health-care industry . Analysts used the ritual of quarterly earnings calls to probe companies on whether their businesses were being helped — or hampered by — the latest trend. Drugs that mimic gut hormones like glucagon-like peptide-1, or GLP-1, were first used […]
Read More
Weight loss drugs are priced substantially higher in the U.S. than in other countries, analysis says
In this photo illustration, a box of the diabetes drug Ozempic rests on a pharmacy counter on April 17, 2023 in Los Angeles, California. Mario Tama | Getty Images Blockbuster weight loss drugs are priced significantly higher in the U.S. than in other large, high-income countries, according to a new analysis released Thursday. The report […]
Read More
Wegovy could prevent up to 1.5 million heart attacks, strokes over 10 years, study says
A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023. Jim Vondruska | Reuters Novo Nordisk’s blockbuster weight loss injection Wegovy could prevent up to 1.5 million heart attacks, strokes and other cardiovascular events in the U.S. over 10 years, according to […]
Read More
UBS says this stock is the ‘best story’ among U.S. large caps, sees more than 15% upside ahead
Eli Lilly has had a great run, but UBS expects about 16% further upside in the coming months as a steady stream of positive news propels the stock higher and revenue growth accelerates. Calling it the “best fundamental story” among U.S. large caps, UBS analyst Colin Bristow on Friday lifted his price target to $612 […]
Read More
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
Liselotte Sabroe | Afp | Getty Images Novo Nordisk on Thursday said it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company’s blockbuster weight loss portfolio. The deal is Novo Nordisk’s latest attempt to capitalize on the weight loss industry gold rush, which began […]
Read More
European marketplaces climb on strong earnings ahead of essential U.S. inflation print
Traders will work at the inventory exchange in Frankfurt, Germany. Daniel Roland | Afp | Getty Photographs LONDON — European markets had been larger on Thursday as investors digested a new spherical of corporate earnings and seemed ahead to a important U.S. inflation print that could present hints about the Federal Reserve’s following financial policy […]
Read More
Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soar
A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. Jim Vondruska | Reuters Novo Nordisk, which makes the weight-loss drug Wegovy, raised its outlook for 2023 Thursday, as it reported soaring sales. The Danish pharmaceutical company reported a 30% increase […]
Read More
Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data
A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. Jim Vondruska | Reuters Novo Nordisk‘s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial – a landmark finding that could put more […]
Read More